Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Breast cancer intrinsic subtypes with prevalent immuno-histochemical profiles and options of treatment [3]

From: Molecular characterization and targeted therapeutic approaches in breast cancer

Intrinsic subtype cDNA microarrays IHC Treatment
Luminal A The highest expression of the ER α gene, GATA-binding protein 3, X-box-binding protein 1, trefoil factor 3, hepatocyte nuclear factor 3 α, and estrogen-regulated LIV-1 ER- and/or PR-positive HER2-negative Ki-67 < 14% Endocrine therapy (chemotherapy for selected patients)
Luminal B Low to moderate expression of the luminal-specific genes, including the ER cluster ER- and/or PR-positive HER2-negative with Ki-67 ≥ 14% Endocrine therapy ± chemotherapy
ER- and/or PR-positive HER2-positive with any Ki-67 Chemotherapy + anti-HER2 therapy + endocrine therapy
HER2-enriched High expression of several genes in the ERBB2 amplicon at 17q22.24, including ERBB2 and GRB7 ER- and PR-negative HER2-positive Chemotherapy + anti-HER2 therapy
Basal-like High expression of keratins 5 and 17, laminin, and fatty acid-binding protein 7 ER- and PR-negative HER2-negative Chemotherapy
  1. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; PR, progesterone receptor.